Agreement launches clinical evaluation of world’s first multi-arm surgical robot
The strategic partnership aims at the medium-term market launch of an innovative robotic solution in Europe and is tailored to Implanet’s product offering.
Boston, Nov. 13, 2025 /OrthoSpineNews/- IMPLANET (Euronext Growth: ALIMP, FR0013470168, PEA-PME eligible), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced the signing of a partnership agreement with 8i Robotics Inc. The first milestone of this agreement focuses on clinical research aimed at achieving compliance European regulations for a supervised surgeon. Robot designed for spine surgery.
IMPLANET also announced that it will be exhibiting alongside 8i Robotics Inc. at the North American Spine Society (NASS) annual meeting (booth #1037) in Denver this week.
Ludovic Lastennet, CEO of IMPLANET, said: “As part of our strategic plan, the signing of this partnership agreement with 8i Robotics Inc., a Canadian manufacturer and innovative player in the field of robotics, places IMPLANET at the center of the clinical evaluation and regulatory registration in Europe of a unique robotic solution in the world. The technical solutions developed by 8i Robotics represent the next step in surgeon-supervised assistive technologies, enabling more efficient robotic procedures and greater patient safety. This new commitment should allow “It will allow us to quickly conclude additional clinical research agreements with leading hospitals in France to complete the regulatory registration of implantable solutions dedicated to robotics in the European market.”
Dr. Brent Bailey, systems engineer at 8i Robotics and veteran medical device developer in surgical microscopy, said: “The 8i Robotics solution offers precise implant placement and minimizes complications by enabling precise navigation to the surgical site. Its compact design, positioned on one side of the surgical table, ensures that clinical staff remain unobstructed and allows for seamless integration of intraoperative imaging tools. We look forward to working with IMPLANET and our partners to achieve CE mark and support surgeons in Europe”.
This clinical and regulatory partnership between IMPLANET and 8i Robotics will allow research with leading French hospitals and the preparation of the CE mark of an innovative robotic solution in Europe. It is an integral part of IMPLANET’s long-term strategic business offering to combine the latest advances and innovations in spine surgery (deformity correction systems, minimally invasive product ranges, robotics, artificial intelligence, etc.) for the global market.
Key technological aspects:
Multi-Arm Intelligence: Three robotic arms working together (an optical imaging head with integrated digital microscope and left and right surgical arms) provide complete coverage of the surgical site, going far beyond traditional screw placement guidance. Advanced Digital Microscope: The industry-leading integrated surgical microscope provides high-resolution viewing with optical magnification and a large working distance, eliminating the need for separate microscopy equipment. This differentiates 8i Robotics from competing multi-arm systems that lack built-in microscopy capabilities.
Next financial communication
Full year 2025 earnings, January 13, 2026, after market close.
About 8i Robotics Inc.
8i Robotics™ introduced the world’s first multi-arm humanoid robotic systems for orthopedic and neurosurgical spine surgery in May 2024, at the American Association of Neurological Surgeons annual meeting in Chicago. 8i Robotics is redefining surgical precision by integrating cutting-edge robotics, electromagnetic navigation and advanced optical imaging technologies. The company’s flagship system represents a revolutionary advancement as the world’s first multi-armed humanoid surgical robot with electromagnetic navigation and an integrated digital microscope. Headquartered in Canada with collaborative partnerships in North America, Europe and Asia, 8i Robotics progresses through regulatory filings while conducting extensive preclinical and clinical trials. The device is currently not available for sale in Canada, the United States or Europe pending regulatory approvals. For more information, visit www.8irobotics.com.
About IMPLANET
IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ®), complemented by the product range of thoraco-lumbar cervical screws, cages and plates, acquired through Orthopedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological and financial partnership with Sanyou Medical, the second largest medical device manufacturer in China. As part of this strategic agreement, IMPLANET developed the Jazz Spinal System™ hybrid fixation system in 2024, a unique new range that presents a comprehensive pedicle screw solution, combined with the most advanced braided implant technology on the market, JAZZ®. IMPLANET’s orthopedic platform is based on the traceability of its products. Protected by four international patent families, JAZZ® has received 510(k) regulatory clearance from the US Food and Drug Administration (FDA), CE Mark in Europe, and ANVISA approval in Brazil. IMPLANET employs 46 people and generated €9.4 million in consolidated revenue in 2024. Headquartered near Bordeaux, France, IMPLANET has operated a US subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris. For more information, visit www.Implanet.com.
US media contact
Paul Williams
Telephone: 310-569-0023
pablo@medialinecommunications.com
